Peak HumanDatabase
    All Research
    PAPER SENESCExpert Consensus2026

    A consensus roadmap from the SENESCENCE2030 network towards precision senescence medicine

    A multi-stakeholder consensus roadmap naming the blocking constraints on clinical senescence medicine: no functional classification of senescent states, no standardised clinically actionable biomarkers, no established regulatory framework for an aging indication. For clinicians fielding senolytic questions, the useful signal is what the field's own consensus does not claim - there is currently no validated way to select patients or define the target cell population.

    Evidence

    4/10

    Emerging Evidence

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    Nature Aging

    Sep 2026

    Authors

    Authorship

    Aniello Cerrato, Antonella Farsetti, Marco Demaria

    01

    Full Abstract

    At the SENESCENCE2030 Annual Conference and Industry-Academia Workshop held in Coimbra, Portugal, in May 2026, researchers, clinicians, industry representatives and policy stakeholders identified the major priorities required to translate recent advances in cellular senescence research into clinical practice. The resulting roadmap emphasizes the need to establish functional classifications of senescent states, develop standardized and clinically actionable biomarkers, advance precision senescence medicine, strengthen translational and regulatory frameworks, and promote international collaboration.

    02

    Key Findings

    1. 01

      Functional classification of senescent states named as a prerequisite for clinical translation

    2. 02

      No standardised, clinically actionable senescence biomarker currently exists

    3. 03

      Precision senescence medicine identified as the intended direction of travel

    4. 04

      Translational and regulatory frameworks named as a blocking constraint

    5. 05

      International collaboration and standardisation emphasised

    03

    Structured Methods

    Study Design
    Expert Consensus
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Multi-stakeholder consensus process at the SENESCENCE2030 Annual Conference and Industry-Academia Workshop, Coimbra, Portugal, May 2026, involving researchers, clinicians, industry representatives and policy stakeholders; published as a Meeting Report.
    Limitations
    A consensus roadmap carries no experimental weight of its own and reflects the priorities and composition of the participating group, which included industry representatives. It reports no new data and makes no claim about the efficacy or safety of any specific compound.
    04

    Citations & References

    Cite this paper

    Aniello Cerrato, Antonella Farsetti, Marco Demaria (2026). A consensus roadmap from the SENESCENCE2030 network towards precision senescence medicine. Nature Aging. https://doi.org/10.1038/s43587-026-01222-y

    DOI

    10.1038/s43587-026-01222-y

    Source

    Publisher

    Journal

    Nature Aging

    05

    Indexing

    Topics

    cellular senescencebiomarkersregulatory scienceconsensus

    Interventions

    senolyticssenomorphicsfisetindasatinib + quercetin
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works